Long-Term Cognitive Outcomes of Esketamine Nasal Spray in Treatment-Resistant Depression: A Preliminary Report.
Pharmaceuticals (Basel, Switzerland) January 27, 2025 Matildes de Freitas Menezes Sobreiro, Paulo Sergio Panse Silveira, Vitor Breseghello Cavenaghi et al. 5 citations
In a small group of eight patients with treatment-resistant depression, six months of adjunctive esketamine nasal spray was associated with improvements in attention, memory, and several executive functions, including working memory, set-shifting, and inhibitory control. Most cognitive gains appeared by three months, though working memory and set-shifting improvements were significant only at six months. Depression severity also decreased over the six-month period, and most cognitive improvements correlated with reduced depression severity. No cognitive decline was observed. The authors note that confirmatory studies are needed.